Kunming Longjin Pharmaceutical Co.,Ltd.
龙津药业
Kunming Longjin Pharmaceutical Co.,Ltd.
Biotech/Healthcare
Longjin Pharmaceutical focuses on the development, research, production, and sale of therapeutic drugs in two major areas: cardiovascular and cerebrovascular diseases, and metabolic diseases. Its flagship product is Longjin’s lyophilized injection of breviscapine.
Latest round: Post-IPO (2022)
Source: ChinaBulls — chinabulls.com
Last updated 2022-06-01
Funding history
Request access to view this section.
Investors
Request access to view this section.
HQ & website
Request access to view this section.
Tags
Request access to view this section.